|
1
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Preusser M, de Ribaupierre S, Wöhrer A,
Erridge SC, Hegi M, Weller M and Stupp R: Current concepts and
management of glioblastoma. Ann Neurol. 70:9–21. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choi J, Stradmann-Bellinghausen B, Yakubov
E, Savaskan NE and Régnier-Vigouroux A: Glioblastoma cells induce
differential glutamatergic gene expressions in human
tumor-associated microglia/macrophages and monocyte-derived
macrophages. Cancer Biol Ther. 16:1205–1213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanada T, Hashizume Y, Tokuhara N,
Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M
and Nishizawa Y: Perampanel: A novel, orally active, noncompetitive
AMPA-receptor antagonist that reduces seizure activity in rodent
models of epilepsy. Epilepsia. 52:1331–1440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vecht C, Duran-Peña A, Houillier C, Durand
T, Capelle L and Huberfeld G: Seizure response to perampanel in
drug-resistant epilepsy with gliomas: Early observations. J
Neurooncol. 133:603–607. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Groot JF, Piao Y, Lu L, Fuller GN and
Yung WK: Knockdown of GluR1 expression by RNA interference inhibits
glioma proliferation. J Neurooncol. 88:121–133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ishiuchi S, Tsuzuki K, Yoshida Y, Yamada
N, Hagimura N, Okado H, Miwa A, Kurihara H, Nakazato Y, Tamura M,
et al: Blockage of Ca(2+)-permeable AMPA receptors suppresses
migration and induces apoptosis in human glioblastoma cells. Nat
Med. 8:971–978. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishiuchi S, Yoshida Y, Sugawara K, Aihara
M, Ohtani T, Watanabe T, Saito N, Tsuzuki K, Okado H, Miwa A, et
al: Ca2+-permeable AMPA receptors regulate growth of human
glioblastoma via Akt activation. J Neurosci. 27:7987–8001. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iwamoto FM, Kreisl TN, Kim L, Duic JP,
Butman JA, Albert PS and Fine HA: Phase 2 trial of talampanel, a
glutamate receptor inhibitor, for adults with recurrent malignant
gliomas. Cancer. 116:1776–1782. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takano T, Lin JH, Arcuino G, Gao Q, Yang J
and Nedergaard M: Glutamate release promotes growth of malignant
gliomas. Nat Med. 7:1010–1015. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wirsching HG and Weller M: Does neuronal
activity promote glioma progression? Trends Cancer. 6:1–3. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rzeski W, Ikonomidou C and Turski L:
Glutamate antagonists limit tumor growth. Biochem Pharmacol.
64:1195–1200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Howes JF and Bell C: Talampanel.
Neurotherapeutics. 4:126–129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Grossman SA, Ye X, Piantadosi S, Desideri
S, Nabors LB, Rosenfeld M, Fisher J and NABTT CNS Consortium:
Survival of patients with newly diagnosed glioblastoma treated with
radiation and temozolomide in research studies in the United
States. Clin Cancer Res. 16:2443–2449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lange F, Weßlau K, Porath K, Hörnschemeyer
J, Bergner C, Krause BJ, Mullins CS, Linnebacher M, Köhling R and
Kirschstein T: AMPA receptor antagonist perampanel affects
glioblastoma cell growth and glutamate release in vitro. PLoS One.
14:e02116442019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hibi S, Ueno K, Nagato S, Kawano K, Ito K,
Norimine Y, Takenaka O, Hanada T and Yonaga M: Discovery of
2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile
(perampanel): A novel, noncompetitive α-amino-3-hydroxy-5-
methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist. J Med
Chem. 55:10584–10600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Izumoto S, Miyauchi M, Tasaki T, Okuda T,
Nakagawa N, Nakano N, Kato A and Fujita M: Seizures and tumor
progression in glioma patients with uncontrollable epilepsy treated
with perampanel. Anticancer Res. 38:4361–4366. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patsalos PN: The clinical pharmacology
profile of the new antiepileptic drug perampanel: A novel
noncompetitive AMPA receptor antagonist. Epilepsia. 56:12–27. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rösche J, Piek J, Hildebrandt G, Grossmann
A, Kirschstein T and Benecke R: Perampanel in the treatment of a
patient with glioblastoma multiforme without IDH1 mutation and
without MGMT promotor methylation. Fortschr Neurol Psychiatr.
83:286–289. 2015.(In German). PubMed/NCBI
|
|
20
|
Salmaggi A, Corno C, Maschio M, Donzelli
S, D'Urso A, Perego P and Ciusani E: Synergistic effect of
perampanel and temozolomide in human glioma cell lines. J Pers Med.
11:3902021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seker F, Cingoz A, Sur-Erdem İ, Erguder N,
Erkent A, Uyulur F, Esai Selvan M, Gümüş ZH, Gönen M, Bayraktar H,
et al: Identification of SERPINE1 as a regulator of glioblastoma
cell dispersal with transcriptome profiling. Cancers (Basel).
11:16512019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pavón MA, Arroyo-Solera I, Céspedes MV,
Casanova I, León X and Mangues R: uPA/uPAR and SERPINE1 in head and
neck cancer: Role in tumor resistance, metastasis, prognosis and
therapy. Oncotarget. 7:57351–57366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E,
et al: Gene expression profiling predicts response to temozolomide
in malignant gliomas. Int J Oncol. 36:1367–1377. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wischhusen J, Naumann U, Ohgaki H,
Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent,
induces p53-dependent and p53-independent glioma cell death.
Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bello MJ, Alonso ME, Amiñoso C, Anselmo
NP, Arjona D, Gonzalez-Gomez P, Lopez-Marin I, de Campos JM,
Gutierrez M, Isla A, et al: Hypermethylation of the DNA repair gene
MGMT: Association with TP53 G:C to A:T transitions in a series of
469 nervous system tumors. Mutat Res. 554:23–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
